Together Trial (@TogetherTrial) header
Together Trial (@TogetherTrial) profile picture

A Multi-Center, Adaptive Platform Randomized Controlled Trial to evaluate the efficacy of repurposed therapies in treating early SARS-CoV-2: the TOGETHER trial

Brazil
Joined January 2021
Photo by Together Trial (@TogetherTrial)
TOGETHER Study finds ivermectin no more beneficial than placebo in reducing hospitalisations or ER observations >6 hours in 12 sites, double-blind, platform RCT in Brazil nejm.org/doi/full/10.1056/NE…
20
2
5
9
In 20 Jan 2021 @TogetherTrial enrolled its first patient. Exactly one year later nobody could predict these waves and variants of concern that are still overcrowding public health worldwide. Still so much to learn! #COVID19 #Omicron #research @NIH @PublicHealth @GloboNews
5
1
1
8
Correction: The switch to three doses of Ivermectin in the TOGETHER Trial occurred before the most recent interim analysis. The trial schema has been updated on the website.
26
2
4
22
The updated TOGETHER Trial schema is now posted to our website. togethertrial.com
7
9
7
27
A well-researched article summarizing the findings of trials, including @TogetherTrial, evaluating the effectiveness of repurposed therapies for outpatient treatment fo COVID-19 by @elandhuis
8
6
2
21
The previous iteration of the TOGETHER Trial evaluating HCQ and LPV/r was stopped by our DSMB for futility - (publication soon). The story of HCQ was one of unnecessary politicisation. Here is a narrative commentary by our team on the Rise and Fall of HCQ. pubmed.ncbi.nlm.nih.gov/3323…
6
2
9
“Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin in the treatment of COVID-19.” - NIH recommendation Feb 11th 2021 Alright. togethertrial.com
7
5
16
"The need for treatments in early disease is paramount. Evidence is quickly emerging that suggests a number of drugs may have a promising effect on reducing COVID-19 disease severity in patients with mild to moderate disease” - Dr. Edward Mills, principal investigator
Our website is now live and our first tweet is out. Check us out at togethertrial.com and follow us for upcoming information on the TOGETHER Trial #covidtrials #covid19
1
1
1
8